Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 52.05
(0.97%)
EUR 52.05
(0.97%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 3.29 EUR | -11.8% |
| 2022 | 3.73 EUR | 35.14% |
| 2021 | 2.76 EUR | 150.91% |
| 2020 | 1.10 EUR | 54.93% |
| 2019 | 0.71 EUR | 102.86% |
| 2018 | 0.35 EUR | 0.0% |
| 2017 | 0.35 EUR | -33.96% |
| 2016 | 0.53 EUR | 32.5% |
| 2015 | 0.40 EUR | -16.67% |
| 2014 | 0.48 EUR | 4.35% |
| 2013 | 0.46 EUR | 17.95% |
| 2012 | 0.39 EUR | 8.33% |
| 2011 | 0.36 EUR | -26.53% |
| 2010 | 0.49 EUR | 19.51% |
| 2009 | 0.41 EUR | 0.0% |
| 2008 | 0.41 EUR | 36.67% |
| 2007 | 0.30 EUR | 233.33% |
| 2006 | 0.09 EUR | -100.0% |
| 2005 | 18.24 Thousand EUR | 57536.65% |
| 2004 | 31.65 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 0.57 EUR | 89.66% |
| 2024 Q1 | 0.29 EUR | -70.71% |
| 2023 FY | - EUR | -11.8% |
| 2023 Q2 | 0.36 EUR | -59.55% |
| 2023 Q1 | 0.89 EUR | -39.04% |
| 2023 Q4 | 0.99 EUR | 1.02% |
| 2023 Q3 | 0.98 EUR | 172.22% |
| 2022 Q4 | 1.46 EUR | 82.5% |
| 2022 FY | - EUR | 35.14% |
| 2022 Q1 | 0.98 EUR | -2.0% |
| 2022 Q2 | 0.52 EUR | -46.94% |
| 2022 Q3 | 0.80 EUR | 53.85% |
| 2021 Q4 | 1.00 EUR | 12.36% |
| 2021 FY | - EUR | 150.91% |
| 2021 Q1 | 0.43 EUR | 65.38% |
| 2021 Q2 | 0.50 EUR | 16.28% |
| 2021 Q3 | 0.89 EUR | 78.0% |
| 2020 Q3 | 0.31 EUR | 10.71% |
| 2020 FY | - EUR | 54.93% |
| 2020 Q1 | 0.25 EUR | 56.25% |
| 2020 Q2 | 0.28 EUR | 12.0% |
| 2020 Q4 | 0.26 EUR | -16.13% |
| 2019 Q2 | 0.17 EUR | 41.67% |
| 2019 Q4 | 0.16 EUR | -38.46% |
| 2019 FY | - EUR | 102.86% |
| 2019 Q1 | 0.12 EUR | 192.68% |
| 2019 Q3 | 0.26 EUR | 52.94% |
| 2018 Q4 | 0.04 EUR | -72.67% |
| 2018 Q3 | 0.15 EUR | 1053.85% |
| 2018 Q2 | 0.01 EUR | -90.71% |
| 2018 Q1 | 0.14 EUR | 3011.11% |
| 2018 FY | - EUR | 0.0% |
| 2017 FY | - EUR | -33.96% |
| 2017 Q4 | 0.00 EUR | -82.69% |
| 2017 Q3 | 0.03 EUR | -86.32% |
| 2017 Q2 | 0.19 EUR | 46.15% |
| 2017 Q1 | 0.13 EUR | 39.78% |
| 2016 Q2 | 0.17 EUR | -10.53% |
| 2016 Q1 | 0.19 EUR | 183.58% |
| 2016 FY | - EUR | 32.5% |
| 2016 Q3 | 0.07 EUR | -58.24% |
| 2016 Q4 | 0.09 EUR | 30.99% |
| 2015 Q1 | 0.13 EUR | 51.16% |
| 2015 FY | - EUR | -16.67% |
| 2015 Q4 | 0.07 EUR | 11.67% |
| 2015 Q3 | 0.06 EUR | -57.14% |
| 2015 Q2 | 0.14 EUR | 7.69% |
| 2014 Q4 | 0.09 EUR | -13.13% |
| 2014 FY | - EUR | 4.35% |
| 2014 Q1 | 0.12 EUR | 37.93% |
| 2014 Q2 | 0.18 EUR | 50.0% |
| 2014 Q3 | 0.10 EUR | -45.0% |
| 2013 Q4 | 0.09 EUR | -10.31% |
| 2013 FY | - EUR | 17.95% |
| 2013 Q1 | 0.11 EUR | -15.38% |
| 2013 Q2 | 0.17 EUR | 54.55% |
| 2013 Q3 | 0.10 EUR | -42.94% |
| 2012 Q4 | 0.13 EUR | 78.08% |
| 2012 FY | - EUR | 8.33% |
| 2012 Q1 | 0.11 EUR | 0.0% |
| 2012 Q3 | 0.07 EUR | -51.33% |
| 2012 Q2 | 0.15 EUR | 36.36% |
| 2011 Q4 | 0.11 EUR | 83.33% |
| 2011 Q2 | 0.17 EUR | 75.26% |
| 2011 Q3 | 0.06 EUR | -64.71% |
| 2011 FY | - EUR | -26.53% |
| 2011 Q1 | 0.10 EUR | 7561.54% |
| 2010 Q3 | 0.11 EUR | -60.71% |
| 2010 Q1 | 0.10 EUR | 0.0% |
| 2010 Q4 | -0.00 EUR | -101.18% |
| 2010 FY | - EUR | 19.51% |
| 2010 Q2 | 0.28 EUR | 180.0% |
| 2009 FY | - EUR | 0.0% |
| 2008 FY | - EUR | 36.67% |
| 2007 FY | - EUR | 233.33% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | - EUR | 57536.65% |
| 2004 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Atrys Health, S.A. | -0.60 EUR | 648.333% |
| Biotechnologies Assets SA | 0.03 EUR | -11951.282% |
| Oryzon Genomics S.A. | -0.06 EUR | 6070.962% |
| Pharma Mar, S.A. | 0.06 EUR | -5081.102% |